TUMOUR TREATMENT AGENT AND KIT CONTAINING LIPOSOMAL GEMCITABINE COMPOSITION Russian patent published in 2021 - IPC A61K9/127 A61K31/7068 A61K47/24 A61K47/28 A61P35/00 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to the field of pharmaceuticals, namely, to a liposomal composition constituting an anti-tumour therapeutic agent. The liposomal composition comprises from 0.1 to 2.0 mg/ml of gemcitabine or hydrochloride thereof in the liposome, formed, in turn, by hydrogenated soy phosphatidyl choline, 1,2-distearoyl-3-phosphatidyl ethanolamine polyethylene glycol and cholesterol, at a certain ratio of the cholesterols to the total amount of lipids forming the liposome, wherein the osmotic pressure of the internal aqueous phase of the liposome is 2 to 8 times greater than the osmotic pressure of the external aqueous phase of the liposome.

EFFECT: invention ensures creation of liposomes containing gemcitabine or a salt thereof as a medicinal product for treatment of cancer, having an acceptable release time, ease of release of the medicinal product, and stability in storage.

4 cl, 1 dwg, 2 tbl, 3 ex